Keywords
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Bibliometrics
Monoclonal antibodies
How to Cite
Abstract
BACKGROUND: Asthma–COPD overlap syndrome (ACO) is characterized by features of both asthma and COPD and is associated with a higher risk of hospital admissions. While several studies have analyzed the scientific production on asthma and COPD separately, little is known about the state of research on the overlap syndrome.
OBJECTIVE: To analyze the scientific output on asthma–COPD overlap (ACO).
METHODOLOGY: A bibliometric study was conducted using Scopus and Web of Science, including original articles published up to 2024. Indicators of productivity, collaboration, and impact were analyzed with the bibliometrix package in RStudio.
RESULTS: A total of 436 articles on ACO were identified. The first publication appeared in 2005, and since 2013 the scientific output has grown markedly, with an annual growth rate of 8.38%. The most productive countries were South Korea (n = 330), the United States (n = 329), and China (n = 312). The thematic analysis of research on ACO showed that the main areas studied are diagnosis and vulnerable populations, as well as the epidemiology and pathophysiology of the disease, while the treatment area remains under development, particularly regarding the study of monoclonal antibodies.
CONCLUSION: The analysis of scientific production on ACO reveals that, despite the sustained increase in research, significant gaps persist regarding therapeutic strategies. Furthermore, research remains limited in several countries with a high disease burden; mapping these areas and regions will be essential to foster the generation of local evidence to guide clinical and public health decision-making.
KEYWORDS: Asthma–Chronic Obstructive Pulmonary Disease Overlap Syndrome (ACO); Asthma; Chronic Obstructive Pulmonary Disease (COPD); Bibliometrics; Monoclonal antibodies.
References
1. Leung C, Sin DD. Asthma-COPD overlap. Chest. 2022; 161 (2): 330-344. doi: 10.1016/j.chest.2021.09.036
2. Alshabanat A, Zafari Z, Albanyan O, Dairi M, FitzGerald JM. Asthma and COPD overlap syndrome (ACOS): a systematic review and meta-analysis. PLoS One. 2015; 10 (9): e0136065. doi: 10.1371/journal.pone.0136065
3. Kim M, Tillis W, Patel P, Davis RM, Asche CV. Association between asthma/chronic obstructive pulmonary disease overlap syndrome and healthcare utilization among the US adult population. Curr Med Res Opin. 2019; 35 (7): 1191-1196. doi:10.1080/03007995.2019.1565531
4. Zhou XL, Zhao LY. Comparison of clinical features and outcomes for asthma-COPD overlap syndrome vs COPD patients: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021; 25 (23): 7342-7356. doi:10.26355/eurrev_202112_27457
5. Hosseini M, Almasi-Hashiani A, Sepidarkish M, Maroufizadeh S. Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis. Respir Res. 2019; 20 (1): 229. doi:10.1186/s12931-019-1198-4
6. Sin DD, Miravitlles M, Mannino DM, et al. What is asthma–COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J. 2016; 48 (3): 664-673. doi:10.1183/13993003.00436-2016
7. Mekov E, Nuñez A, Sin DD, et al. Update on asthma-COPD overlap (ACO): a narrative review. Int J Chron Obstruct Pulmon Dis. 2021; 16: 1783-1799. doi:10.2147/COPD.S312198
8. Alsayed AR, Abu-Samak MS, Alkhatib M. Asthma-COPD overlap in clinical practice (ACO_CP 2023): toward precision medicine. J Pers Med. 2023; 13 (4): 677. doi:10.3390/jpm13040677
9. Sun J, Bai S, Zhao J, et al. Mapping knowledge structure and research of the biologic treatment of asthma: a bibliometric study. Front Immunol. 2023; 14: 1034755. doi:10.3389/fimmu.2023.1034755
10. Venkata AN. Asthma–COPD overlap: review of diagnosis and management. Curr Opin Pulm Med. 2020; 26 (2): 155-161. doi:10.1097/MCP.0000000000000649
11. Sun Y, Jiang F, Li R, Xiao L. The future landscape of immunology in COPD: a bibliometric analysis. Respir Med. 2023; 220: 107462. doi: 10.1016/j.rmed.2023.107462
12. Dey S, Eapen MS, Chia C, Gaikwad AV, et al. Pathogenesis and clinical features of asthma-COPD overlap, and therapeutic modalities. Am J Physiol Lung Cell Mol Physiol. 2022; 322 (1): L64-L83. doi:10.1152/ajplung.00249.2021
13. Aria M, Cuccurullo C. Bibliometrix: an R-tool for comprehensive science mapping analysis. J Informetr. 2017; 11 (4): 959-975. doi: 10.1016/j.joi.2017.08.007
14. Petty TL. Asthma and chronic obstructive pulmonary disease overlap syndrome (ACOS): recognition, mechanisms, and treatment. Ann Allergy Asthma Immunol. 2005; 94 (3 Suppl 1): S27-S32. doi:10.1016/S1081-1206(10)61395-0
15. Global Initiative for Asthma; Global Initiative for Chronic Obstructive Lung Disease. Diagnosis of Diseases of Chronic Airflow Limitation: Asthma, COPD and Asthma–COPD Overlap Syndrome (ACOS). Updated 2015. http://www.ginasthma.org
16. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2015. http://www.ginasthma.org/
17. Wang Z, Li Y, Gao Y, et al. Global, regional, and national burden of asthma and its attributable risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Respir Res. 2023; 24 (1): 169. doi:10.1186/s12931-023-02475-6
18. Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. The Lancet Respiratory Medicine. 2022; 10 (5): 447-458. doi:10.1016/S2213-2600(21)00511-7
19. Xu X, Zhang L, Li J, et al. Bibliometric analysis of asthma research: trends and hotspots. Respir Res. 2021; 22: 110. doi:10.1186/s13670-021-00470-7
20. Cao Y, Zhang Y, Li Y, et al. Global trends in COPD research: a bibliometric analysis. Int J Chron Obstruct Pulmon Dis. 2024; 19: 45-58. doi:10.2147/COPD.S347771
21. Li X, Zhang Y, Liu Y, et al. Phenotypes and prevalence in obstructive airway diseases: A bibliometric review. J Clin Med. 2020; 9: 3456. doi:10.3390/jcm9113456
22. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD. 2025. https://goldcopd.org/
23. Pavord ID, Korn S, Howarth P, et al. Biomarkers in asthma: eosinophils, FeNO, and precision therapy. Lancet Respir Med. 2020; 8 (12): 1025-1038. doi:10.1016/S2213-2600(20)30315-7
24. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2025. https://ginasthma.org/
25. Ortega HG, Liu MC, Pavord ID, Brusselle GG, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014; 371 (13): 1198-1207. doi:10.1056/NEJMoa1403290
26. Pranckutė R. Web of Science (WoS) and Scopus: the titans of bibliographic information in today's academic world. Publications. 2021; 9 (1): 12. doi:10.3390/publications9010012
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2026 Revista Alergia México